世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000028599

非小細胞肺がん:2029年までの薬剤予測および世界市場分析

GlobalData

Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029

発刊日 2020/12/31

言語英語

体裁PDF/181ページ

「PDF」版181ページ

0000028599

非小細胞肺がん:2029年までの薬剤予測および世界市場分析
Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029

10,995 USD

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

非小細胞肺がん(NSCLC)は、現在世界で最も多いがんであり、男女のがん死亡原因の第1位です。肺がんの全発生症例のうち、約85%がNSCLCサブタイプです。NSCLC患者は、通常、末期に診断されることが多く、予後不良となります。前回の世界市場予測(2015年~2025年)以降、進行期の患者、特に転移期の患者の治療に大きな変化が見られるようになりました。NSCLCはまだ治癒可能とは考えられていませんが、医師はこの分野での進歩に熱心です。無増悪生存期間と全生存期間の改善によって示されるように、新しい薬剤はより耐久性のある治療効果を提供しています。進歩は、チェックポイント阻害薬のファーストラインへの導入と、患者の転帰を劇的に改善した複数の次世代標的治療薬によって示されています。

これらの最近の成功は、予測期間中にさらに発展していくでしょう。現在の治療法では十分な治療効果が得られていないニッチな分子異常を標的とした薬剤の開発により、個別化医療はより正確なものになるでしょう。さらに、新規薬剤により、新たに作用する変異を標的とした治療が可能になるでしょう。これらの標的薬と免疫腫瘍学(IO)をベースとした治療法を、特定の患者集団に対するネオアジュバントおよびアジュバントの設定で効果的なコンビナトリアルレジメンで戦略的に使用することも、予測期間中に治療の展望を変えることが期待されています。

GlobalDataは、2019~2029年の予測期間に29社の新規参入企業の参入を見込んでいます。このレポートでは、GlobalDataは各NSCLC治療の臨床的および商業的可能性を評価し、市場の成長を予測し、新たな商業的機会を特定しています。

■調査範囲

  • 疫学、病因、病態、症状、治療ガイドラインなど、NSCLCを概説します。
  • 市場収益、年間治療費、主要なパイプライン製品の売上予測を明らかにします。
  • 既存治療およびパイプライン治療、アンメットニーズと機会、NSCLC治療薬の売上げを促す/抑制する要因など、関連事項などを取り上げます。
  • パイプライン分析:さまざまな開発段階に渡る評価した包括的データ、開発中の新たな動向、開発後期候補化合物の概要を提供します。
  • 同市場における現在および将来の競合分析、市場の促進・抑制要因の分析を提供します。

レポート詳細

目次

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 NSCLC: Executive Summary
2.1 The NSCLC Market Will Expand to $32.9B in 2029
2.2 Targeting Large Patient Populations in the First Line, with a Focus on Establishing New Actionable Mutations and Label Expansions for Premium Products into Earlier Lines
2.3 Opportunities Remain for Tackling Primary and Acquired Resistance to Targeted and IO Based Therapies
2.4 First-in-Class Approvals for Novel Actionable Mutations and Targeting Resistance
2.5 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.4.3 Diagnosed Incident Cases of NSCLC
5.4.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
5.4.5 Diagnosed Incident Cases of NSCLC by Histological Types
5.4.6 Mutations Among Diagnosed Incident Cases of Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma
5.4.7 Five-Year Diagnosed Prevalent Cases of NSCLC
5.5 Epidemiological Forecast for NSCLC, 2019-2029
5.5.1 Diagnosed Incident Cases of NSCLC
5.5.2 Sex-Specific Diagnosed Incident Cases of NSCLC
5.5.3 Age-Specific Diagnosed Incident Cases of NSCLC
5.5.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
5.5.5 Diagnosed Incident Cases of NSCLC by Histological Type
5.5.6 Diagnosed Incident Cases of Non-Squamous Cell Carcinoma by Mutations: Genomic Biomarkers, EGFR and KRAS Mutations
5.5.7 Diagnosed Incident Cases of Squamous Cell Carcinoma by Mutations
5.5.8 Five-Year Diagnosed Prevalent Cases of NSCLC
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 COVID-19 Impact
5.6.3 Limitations of the Analysis
5.6.4 Strengths of the Analysis

6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan
6.5 China

7 Competitive Assessment
7.1 Overview

8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Increased Education, Application, and Refinement of Comprehensive Molecular Testing
8.3 Primary and Acquired Resistance to Immunotherapy
8.4 Personalized Approaches to Tackling Resistance
8.5 Improving Curative Options and Patient Outcomes for Those Without Actionable Mutations

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development

10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Merck & Co.
10.4 AstraZeneca
10.5 Roche
10.6 Eli Lilly
10.7 BMS
10.8 Pfizer
10.9 Boehringer Ingelheim
10.10 Novartis
10.11 Future players

11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 5EU
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 Japan
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 US
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
11.5 China
11.5.1 Forecast
11.5.2 Key Events
11.5.3 Drivers and Barriers

12 Appendix

List of Tables
Table 1: NSCLC: Key Metrics in the 8MM
Table 2: Histologies and Subtypes in NSCLC
Table 3: TNM descriptors used in the AJCC/IASLC Lung Cancer Staging System
Table 4: Overview of the AJCC/IASLC staging system for NSCLC.
Table 5: Risk Factors and Comorbidities for NSCLC
Table 6: 8MM, Diagnosed Incident Cases of NSCLC by Stage at Diagnosis, Ages ≥18 Years, Both Sexes, N, 2019
Table 7: 8MM, Diagnosed Incident Cases of Non-Squamous Cell Carcinoma by Immunotherapy and Genomic Biomarkers, Ages ≥18 Years, Both Sexes, N, 2019
Table 8: 8MM, Diagnosed Incident Cases of Squamous Cell Carcinoma by Mutations, Ages ≥18 Years, Both Sexes, N, 2019
Table 9: Biomarker Testing Rates (%) in Nonsquamous NSCLC in 2019
Table 10: Treatment Guidelines for NSCLC in the 8MM
Table 11: Country Profile - US
Table 12: Country Profile - 5EU
Table 13: Country Profile - Japan
Table 14: Country Profile - China
Table 15: Leading Treatments for NSCLC, 2019
Table 16: Merck’s NSCLC Portfolio Assessment, 2019
Table 17: AstraZeneca’s NSCLC Portfolio Assessment, 2019
Table 18: Roche’s NSCLC Portfolio Assessment, 2019
Table 19: Eli Lilly’s NSCLC Portfolio Assessment, 2019
Table 20: BMS’s NSCLC Portfolio Assessment, 2019
Table 21: Pfizer’s NSCLC Portfolio Assessment, 2019
Table 22: Boehringer Ingelheim’s NSCLC Portfolio Assessment, 2019
Table 23: Novartis’ NSCLC Portfolio Assessment, 2019
Table 24: Future players in NSCLC Portfolio Assessment, 2019
Table 25: NSCLC Market - Global Drivers and Barriers, 2019-2029
Table 26: Key Events Impacting Sales for NSCLC in the 5EU, 2019-2029
Table 27: NSCLC Market - Drivers and Barriers in the 5EU, 2019-2029
Table 28: Key Events Impacting Sales for NSCLC in Japan, 2019-2029
Table 29: NSCLC Market - Global Drivers and Barriers in Japan, 2019-2029
Table 30: Key Events Impacting Sales for NSCLC in the US, 2019-2029
Table 31: NSCLC Market - Drivers and Barriers in the US, 2019-2029
Table 32: Key Events Impacting Sales for NSCLC in China, 2019-2029
Table 33: NSCLC Market - Global Drivers and Barriers in China, 2019-2029
Table 34: Key Historical and Projected Launch Dates for NSCLC
Table 35: Key Historical and Projected Patent Expiry Dates for NSCLC
Table 36: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for NSCLC in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in NSCLC During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of NSCLC During the Forecast Period
Figure 4: 8MM, Diagnosed Incidence of NSCLC, Men, Ages ≥18 Years, 2009-2029
Figure 5: 8MM, Diagnosed Incidence of NSCLC, Women, Ages ≥18 Years, 2009-2029
Figure 6: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of NSCLC
Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NSCLC by Histology Types
Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma by PD-L1, TMB, EGFR, KRAS, BRAF V600E, and MET Exon 14 Mutations
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Non-Squamous Cell Carcinoma Exon 18, Exon 19, Exon 20, Exon 21, KRAS G12C, KRAS G12D, KRAS G12V, ALK, BRAF, ROS1, RET, NTRK1, and HER2 Mutations
Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Squamous Cell Carcinoma by FGFR1, PIK3CA, DDR2, PTEN, ALK, ROS1, BRAF, and RET Mutations
Figure 12: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of NSCLC
Figure 13: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages ≥18 Years, N, 2019
Figure 14: 8MM, Diagnosed Incident Cases of NSCLC, by Sex, Ages ≥18 Years, N, 2019
Figure 15: 8MM, Diagnosed Incident Cases of NSCLC by Age, Both Sexes, N, 2019
Figure 16: 8MM, Diagnosed Incident Cases of NSCLC by Histological Type, Ages ≥18 Years, Both Sexes, N, 2019
Figure 17: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Ages ≥18 Years, Both Sexes, N, 2019
Figure 18: An Overview of the Treatment Algorithm in Non-invasive and Invasive NSCLC
Figure 19: The Current Paradigm for Biomarker-Driven Treatment in NSCLC
Figure 20: Unmet Needs and Opportunities in Non-small Cell Lung Cancer
Figure 21: Overview of the Development Pipeline in NSCLC
Figure 22: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to be Licensed for NSCLC in the 8MM During the Forecast Period
Figure 23: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of NSCLC During the Forecast Period
Figure 24: Analysis of the Company Portfolio Gap in NSCLC During the Forecast Period
Figure 25: Global (8MM) Sales Forecast by Country for NSCLC in 2019 and 2029
Figure 26: Sales Forecast by Class for NSCLC in the 5EU in 2019 and 2029
Figure 27: Sales Forecast by Class for NSCLC in Japan in 2019 and 2029
Figure 28: Sales Forecast by Class for NSCLC in the US in 2019 and 2029
Figure 29: Sales Forecast by Class for NSCLC in China in 2019 and 2029

この商品のレポートナンバー

0000028599

TOP